Skip to main content
Clinical Trials/NCT01527799
NCT01527799
Completed
N/A

The Physiologic Assessment of Exercise Capacity in Pediatric Sickle Cell Anemia

Ann & Robert H Lurie Children's Hospital of Chicago1 site in 1 country60 target enrollmentJune 2009

Overview

Phase
N/A
Intervention
Not specified
Conditions
Sickle Cell Anemia
Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Enrollment
60
Locations
1
Primary Endpoint
VO2 max on cardiopulmonary exercise test
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to use comprehensive exercise testing to examine causes of exercise limitation in children and young adults with sickle cell anemia.

Detailed Description

Although the burden of sickle cell anemia (SCA) on affected individuals is significant, few studies have examined the influence of having SCA on such measures of physical function as exercise capacity. Moreover, the physiologic basis of poor physical functioning in children with SCA is unknown and has not been studied extensively. The purpose of this proposal is to use cardiopulmonary exercise testing (CPET) to gain a comprehensive understanding of exercise capacity, as a measure of physical function, in children and young adults with SCA. The specific aims of this project are to: 1) Measure peak oxygen consumption (VO2), the reference standard for exercise capacity, in children and young adults with SCA classified by primary pathophysiologic contributor to their decreased exercise capacity, and 2) Examine the acute inflammatory response, measured by an increase in soluble vascular cell adhesion molecule (sVCAM) activity, in subjects undergoing CPET. These aims will be performed in 60 subjects with SCA and 30 matched controls without SCA. In a secondary analysis, we will also study the impact of baseline exercise capacity and the inflammatory response to exercise on short and long-term disease related morbidity. This study is essential because it will address several areas of exercise capacity, including the physiologic contributors to exercise limitation that remain fundamental knowledge gaps in SCA.

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
July 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Robert I. Liem

Attending Physician, Hematology, Oncology,Cell Transplantation

Ann & Robert H Lurie Children's Hospital of Chicago

Eligibility Criteria

Inclusion Criteria

  • age 10 to 21 years old; AND
  • Hb SS or S-β0 thalassemia disease, confirmed by hemoglobin analysis

Exclusion Criteria

  • inability to perform maximal testing due to physical limitation (e.g. stroke or avascular necrosis); OR
  • history of exercise-induced syncope or arrhythmias. Subjects will wait at least 2 weeks following any vaso-occlusive pain episode and 12 weeks following any disease-related complication requiring transfusion support. Individuals on hydroxyurea will be eligible. A total of 30 controls without SCA or sickle cell trait will be matched for age, sex and race and recruited from the siblings, friends or relatives of subjects enrolled on this study

Outcomes

Primary Outcomes

VO2 max on cardiopulmonary exercise test

Time Frame: Baseline

Secondary Outcomes

  • Change in VCAM level in response to exercise testing(Baseline (pre-exercise) and Post-exercise)
  • Skin fold measurements to detemine percent body fat(Baseline)
  • All patient reported pain episodes(Every 2 months up to 2 years after baseline)
  • Change in secondary biomarkers in response to exercise test(Baseline (Pre-exercise) and Post-exercise)

Study Sites (1)

Loading locations...

Similar Trials